Managing Acute Heart Failure And Cardiogenic Shock is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Managing Acute Heart Failure And Cardiogenic Shock. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
How non-animal models are redefining oncology drug safety
The FDA issued draft guidance to reduce animal testing for oncology drugs, allowing sponsors to use non-animal methods for certain safety and efficacy assessments.
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
The FDA has approved the first treatment for chronic hepatitis delta virus (HDV) infection, addressing a severe form of viral hepatitis with high mortality.
Your patient's child could be exposed to hidden tobacco dangers
The FDA issued warnings to retailers distributing illegal tobacco products designed to resemble common items, posing a significant public health risk, particularly to children.
BHT, ADA, and food chemicals: When 'safe' isn't forever
The FDA finalized its post-market assessment program for food chemicals, immediately launching reassessments of butylated hydroxytoluene (BHT) and adenosine deaminase (ADA). This move signals a shift towards proactive safety evaluations for substances alrea...
Is the future of drug discovery already on your pharmacy shelf?
The FDA is streamlining drug repurposing, leveraging existing data to identify new indications and expedite therapies for unmet medical needs.
A bureaucratic voucher is now driving rare disease drug development
The FDA granted its seventh priority review voucher, incentivizing drug development for rare pediatric and tropical diseases.
Drug approvals: FDA's pivot to speed and supply. Can both truly thrive?
The FDA selected seven participants for its PreCheck pilot program, aiming to streamline drug manufacturing inspections and enhance supply chain resilience.
Melatonin: Adjunctive, non-opioid for chronic musculoskeletal pain?
Melatonin, a hormone known for sleep regulation, may reduce chronic musculoskeletal pain, offering a potential non-opioid treatment option.
Bilingualism and dementia: Is it delay, or true prevention?
Speaking multiple languages may not directly lower dementia risk, but it could delay symptom onset by enhancing cognitive reserve, a mechanism distinct from disease prevention.